16 Million Doses of Covid-19 Vaccine Raw Materials Arrive in BioFarma

A total of 16 million raw materials of the Covid-19 vaccine from Sinovac have arrived at Soekarno Hatta Airport on March 25, 2021, and will soon be taken to BioFarma. As of the date (25/3) as many as 53.5 million doses of raw materials have been received biofarma.

(Tangerang 25/3) Today, March 25, 2021, Bio Farma again received a bulk shipment of Sinovac vaccine in the form of Ready to Fill (RTF) fourth wave.  The amount of raw materials received as much as 16 million doses (including overfill). The arrival of raw materials from Sinovac was witnessed directly by the Deputy Minister of Health of the Republic of Indonesia Dante Saksono.

In his brief statement, Dante said the Government should combine the use of various brands of COVID-19 vaccines in order to meet the needs of vaccines for the entire target population. No vaccine manufacturer in the world can meet all the demands of major countries such as Indonesia.

"The availability of vaccines is vital in maintaining the smooth running of government-run vaccination programs. Because in the current pandemic emergency, the whole world is scrambling for vaccines. Therefore, the vaccine available is the best vaccine to use" said Dante.

Spokesperson and Corporate Secretary of Biofarma said the total bulk of vaccines from Sinovac that we have received to date as many as 53.5 million vaccines, which have begun to be produced gradually in Biofarma starting January 13, 2021. From the number of vaccines in bulk form gradually, will produce approximately 43 million doses of finished products.

"Since the delivery of the first Covid-19 vaccine raw materials in January 2021 ago, until today (25/3), we have started producing since January 13, 2021 and have produced approximately 24 million doses, and of these, the Covid-19 vaccine produced in Bio Farma, after obtaining a lot of release from BPOM, we have distributed as many as 16.98 million doses to all provinces in Indonesia" he said.

Bambang added, for raw materials that come today, will start to enter the production process at Biofarma is expected on April 4 - April 16, 2021.

If calculated from the first stage to the seventh stage, the vaccine that Indonesia has received both in its finished form from Sinovac, the bulk form of Sinovac and the one from AstraZeneca vaccine from COVAX/GAVI, amounts to approximately 57.6 million doses of vaccine.

Thus, the total vaccine available in Indonesia to date amounts to 47.1 million doses, consisting of: 3 million final doses of CoronaVac products, 43 million doses of Covid-19 vaccine produced by Bio Farma, and 1.1 million final doses of AstraZeneca vaccine products from Covax/GAVI. The total overall vaccine from Sinovac and AstraZeneca has been distributed as of March 25, 2021 as much as 20.8 million doses, consisting of 3 million doses of CoronaVac vaccine, 16.98 million doses of Bio Farma Covid-19 vaccine and 830,640 doses of AstraZeneca vaccine.